Amir Hajrasouliha is an Ophthalmology physician affiliated with Midwest Eye Institute. OpenAlex indexes 105 publications with 1,655 citations (h-index 21).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1160 W Michigan St
Indianapolis, IN 462025209
Telephone
317-944-2020Provider last certified this registry record 20 May 2025.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Carl Zeiss Meditec USA, Inc.Program year20241 payment
- Bausch & Lomb Americas Inc.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
96.9%Antineovascularisation agents95.6%Faricimab-svoa100%Part B, office-administered≥19 patientsCorticosteroid0.5%Prednisolone Acetate100%Part D<11 patients+ 2 more classes in this area
Cancer & immunology
2.7%Vascular Endothelial Growth Factor Inhibitor2.7%Aflibercept100%Part B, office-administered≥20 patientsMetabolism & gastrointestinal
0.4%Anticholinergic0.4%Atropine Sulfate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2022–2023 per NIH RePORTER. The latest:
- Gold nanoparticle Neurosensory Epiretinal Implant to Treat Photoreceptor Vision Loss
Indiana University Indianapolis
FY2023$198,125R21EY032652 - Gold nanoparticle Neurosensory Epiretinal Implant to Treat Photoreceptor Vision Loss
Indiana University Indianapolis
FY2022$237,750R21EY032652
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Toxicity analysis of gold nanoparticle formulations used for intraocular applications
Scientific Reports
2025 - Advances in ophthalmic therapeutic delivery: A comprehensive overview of present and future directions
Survey of Ophthalmology
2024 - The Smart Campus as a Testing Ground for Smart Cities
2021 ASEE Virtual Annual Conference Content Access Proceedings
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Louis Cantor, MD
Midwest Eye Institute
Raj Maturi, MD
Midwest Eye Institute
Richard Burgett, MD
Midwest Eye Institute
Shaohui Liu, MD
Midwest Eye Institute
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”